Velphoro is a chewable tablet used to treat hyperphosphatemia in adults. It contains the active ingredient ferric citrate [1]. Ferric citrate works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [2].
How does Velphoro work to lower phosphate?
Velphoro's mechanism of action involves binding to dietary phosphate within the digestive system. When administered with meals, the ferric iron in Velphoro forms insoluble complexes with phosphate. These complexes are then excreted from the body, thereby reducing the overall amount of phosphate absorbed into the bloodstream [1][2].
What is Velphoro prescribed for?
Velphoro is indicated for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis [1]. Hyperphosphatemia is a condition characterized by abnormally high levels of phosphate in the blood, often seen in individuals with impaired kidney function as the kidneys are responsible for excreting excess phosphate [3].
When does the patent for Velphoro expire?
The patent landscape for Velphoro, like other medications, is complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing, and methods of use. Information regarding the specific expiry dates of Velphoro patents can be found on specialized patent tracking websites. For instance, DrugPatentWatch.com provides detailed patent information for various pharmaceuticals, which can help determine exclusivity periods and potential dates for generic entry [4].
What are the side effects of Velphoro?
Common side effects associated with Velphoro include diarrhea, nausea, and vomiting [1]. Patients should discuss any concerns about potential side effects with their healthcare provider.
How does Velphoro compare to other phosphate binders?
Velphoro belongs to a class of drugs known as phosphate binders. Other phosphate binders include calcium-based binders (e.g., calcium acetate, calcium carbonate), non-calcium, non-aluminum binders (e.g., sevelamer carbonate, sevelamer hydrochloride), and aluminum-based binders (though less commonly used due to toxicity concerns) [3]. Velphoro, containing ferric citrate, offers an alternative mechanism and profile compared to these other agents. Its efficacy and tolerability can vary among individual patients, and the choice of phosphate binder is typically individualized by a physician based on the patient's condition and other factors.
What is the typical dosage for Velphoro?
The starting dose of Velphoro is typically 500 mg (which is equivalent to 1 tablet) taken three times daily with meals. Dosing is then adjusted based on serum phosphate levels [1].
Are there any precautions or warnings for Velphoro?
Patients taking Velphoro should be monitored for iron overload, as ferric citrate contains iron. Caution is advised in patients with iron deficiency anemia or other conditions where iron accumulation is a concern [1].
What are the regulatory approvals for Velphoro?
Velphoro has received marketing authorization in various regions, including the United States and Europe [1].
What is the active ingredient in Velphoro?
The active ingredient in Velphoro is ferric citrate [1].
Where can I find more information on Velphoro's patent status?
Detailed information on Velphoro's patent status, including expiry dates and any related litigation, can be accessed through specialized patent databases and pharmaceutical intelligence services. DrugPatentWatch.com is a resource that offers comprehensive data on drug patents [4].
---
Sources
1. https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205054s000lbl.pdf
3. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/hyperphosphatemia
4. https://drugpatentwatch.com/